CPRX Stock Price, Catalyst Pharmaceuticals Quote, Chart

Market Summary

USD16.49+0.09

Market Closed

0.55%

CPRX Alerts

1 major insider sales recently.

CPRX Stock Price

View Fullscreen

CPRX RSI Chart

CPRX Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

29.91

Price/Sales (Trailing)

4.73

EV/EBITDA

18.75

Price/Free Cashflow

11.94

CPRX Price/Sales (Trailing)

CPRX Profitability

EBT Margin

20.98%

Return on Equity

11.6%

Return on Assets

10.07%

Free Cashflow Yield

8.37%

CPRX Fundamentals

CPRX Revenue

Revenue (TTM)

411.3M

Rev. Growth (Yr)

15.4%

Rev. Growth (Qtr)

-10.91%

CPRX Earnings

Earnings (TTM)

65.1M

Earnings Growth (Yr)

-21.28%

Earnings Growth (Qtr)

-33.2%

Breaking Down CPRX Revenue

Last 7 days

3.5%

Last 30 days

3.1%

Last 90 days

17.8%

Trailing 12 Months

35.2%

How does CPRX drawdown profile look like?

CPRX Financial Health

Current Ratio

5.09

CPRX Investor Care

Shares Dilution (1Y)

11.35%

Diluted EPS (TTM)

0.55

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	411.3M	0	0	0
2023	256.5M	302.9M	348.4M	398.2M
2022	153.7M	170.5M	191.8M	214.2M
2021	120.1M	126.9M	133.5M	140.8M
2020	119.0M	119.8M	118.2M	119.1M
2019	36.6M	54.6M	72.7M	102.3M
2018	0	0	0	18.5M
2010	0	0	0	489.0K

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Catalyst Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	tierney david s	sold	-392,000	15.68	-25,000	-
Apr 08, 2024	tierney david s	acquired	100,250	4.01	25,000	-
Mar 27, 2024	elsbernd brian	sold	-411,000	16.44	-25,000	chief compliance/legal officer
Feb 15, 2024	ingenito gary	acquired	-	-	10,000	chief med. & reg. officer
Feb 15, 2024	elsbernd brian	sold (taxes)	-	-	-2,353	chief compliance/legal officer
Feb 15, 2024	ingenito gary	sold (taxes)	-	-	-2,435	chief med. & reg. officer
Feb 15, 2024	del carmen jeffrey	sold (taxes)	-	-	-3,125	chief commercial officer
Feb 15, 2024	daly richard j	acquired	-	-	4,000	president and ceo
Feb 15, 2024	del carmen jeffrey	acquired	-	-	10,667	chief commercial officer
Feb 15, 2024	sundaram preethi	acquired	-	-	16,667	chief strategy officer

Which funds bought or sold CPRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Ikarian Capital, LLC	added	2.48	-240,468	8,263,070	0.91%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-31.49	-544,744	1,009,880	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	4.26	-19,474	1,695,330	-%
May 16, 2024	Virtus Investment Advisers, Inc.	unchanged	-	-5,841	107,005	0.08%
May 16, 2024	HANCOCK WHITNEY CORP	added	43.51	172,318	649,841	0.02%
May 16, 2024	Creekmur Asset Management LLC	sold off	-100	-2,858	-	-%
May 16, 2024	COMERICA BANK	added	9.36	29,070	815,448	-%
May 15, 2024	Point72 Asset Management, L.P.	reduced	-15.84	-1,685,960	6,661,740	0.02%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	4.47	-150,504	15,960,400	-%
May 15, 2024	Cetera Advisors LLC	new	-	401,242	401,242	-%

Are Funds Buying or Selling CPRX?

Are funds buying CPRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CPRX

No. of Funds

CPRX Alerts

1 major insider sales recently.

Unveiling Catalyst Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	6.68%	7,120,417	SC 13G/A
Feb 12, 2024	flynn james e	8.34%	8,888,901	SC 13G/A
Jan 25, 2024	state street corp	6.37%	6,787,332	SC 13G/A
Jan 22, 2024	blackrock inc.	14.8%	15,821,401	SC 13G/A
Feb 14, 2023	armistice capital, llc	0%	0	SC 13G/A
Feb 10, 2023	flynn james e	5.65%	5,884,448	SC 13G/A
Feb 09, 2023	vanguard group inc	6.50%	6,768,741	SC 13G
Feb 08, 2023	state street corp	7.57%	7,873,314	SC 13G/A
Jan 26, 2023	blackrock inc.	15.1%	15,690,326	SC 13G/A
Jan 20, 2023	blackrock inc.	15.1%	15,690,326	SC 13G/A

Recent SEC filings of Catalyst Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	ARS	ARS
Apr 10, 2024	DEF 14A	DEF 14A
Apr 08, 2024	144	Notice of Insider Sale Intent
Mar 28, 2024	4	Insider Trading
Mar 27, 2024	144	Notice of Insider Sale Intent
Mar 13, 2024	8-K	Current Report
Feb 29, 2024	8-K	Current Report

Peers (Alternatives to Catalyst Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Catalyst Pharmaceuticals Inc News

Latest updates

Catalyst Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-10.9%	99.00	111	103	100	85.00	61.00	57.00	53.00	43.00	38.00	36.00	36.00	30.00	31.00	29.00	30.00	29.00	30.00	31.00	29.00	12.00
Operating Expenses	3.6%	71.00	69.00	140	53.00	50.00	30.00	32.00	25.00	26.00	26.00	22.00	21.00	20.00	-	-	-	-	-	-	18.00	13.00
S&GA Expenses	11.7%	47.00	42.00	34.00	28.00	30.00	14.00	14.00	13.00	16.00	13.00	12.00	12.00	13.00	13.00	10.00	11.00	10.00	11.00	8.00	9.00	8.00
R&D Expenses	30.9%	3.00	2.00	84.00	4.00	4.00	4.00	8.00	4.00	3.00	5.00	4.00	4.00	3.00	4.00	4.00	4.00	4.00	6.00	5.00	5.00	3.00
EBITDA Margin	-11.5%	0.21*	0.24*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-51.0%	6.00	12.00	-7.26	11.00	8.00	8.00	3.00	7.00	4.00	4.00	4.00	4.00	2.00	-2.71	-31.60	1.00	1.00	0.00	1.00	0.00	-
Earnings Before Taxes	-37.7%	29.00	47.00	-38.02	49.00	37.00	33.00	26.00	28.00	17.00	13.00	14.00	16.00	10.00	9.00	12.00	10.00	11.00	8.00	14.00	11.00	-0.64
EBT Margin	-11.6%	0.21*	0.24*	0.23*	0.48*	0.49*	0.49*	0.44*	0.43*	0.39*	0.37*	0.36*	0.36*	0.34*	-	-	-	-	-	-	-	-
Net Income	-33.2%	23.00	35.00	-30.76	38.00	30.00	25.00	23.00	22.00	13.00	9.00	10.00	12.00	8.00	11.00	43.00	10.00	10.00	8.00	14.00	11.00	-0.64
Net Income Margin	-11.7%	0.16*	0.18*	0.18*	0.38*	0.39*	0.39*	0.35*	0.32*	0.29*	0.28*	0.31*	0.59*	0.60*	-	-	-	-	-	-	-	-
Free Cashflow	-42.9%	32.00	56.00	45.00	31.00	12.00	40.00	41.00	26.00	8.00	19.00	22.00	16.00	3.00	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	37.6%	647	470	413	444	407	376	333	267	247	238	223	209	197	192	175	131	118	112	97.00	78.00	61.00
Current Assets	84.5%	405	219	192	241	199	321	276	243	221	210	193	176	162	159	143	131	117	111	91.00	72.00	55.00
Cash Equivalents	125.5%	310	138	121	179	148	298	256	211	178	171	155	135	127	130	117	115	102	90.00	45.00	23.00	19.00
Inventory	27.5%	20.00	16.00	9.00	11.00	10.00	7.00	7.00	8.00	8.00	8.00	7.00	7.00	4.00	5.00	5.00	2.00	2.00	2.00	1.00	0.00	0.00
Net PPE	9.5%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	3.7%	85.00	82.00	65.00	69.00	74.00	75.00	63.00	26.00	27.00	31.00	25.00	20.00	19.00	23.00	18.00	20.00	18.00	25.00	19.00	15.00	10.00
Current Liabilities	4.6%	80.00	76.00	58.00	53.00	57.00	58.00	45.00	22.00	23.00	27.00	21.00	16.00	14.00	23.00	18.00	20.00	18.00	24.00	18.00	14.00	9.00
Shareholder's Equity	44.7%	561	388	349	375	334	300	270	241	220	207	199	189	179	170	157	111	100	88.00	78.00	63.00	51.00
Retained Earnings	19.2%	145	121	86.00	117	79.00	50.00	24.00	2.00	-15.62	-26.31	-32.54	-37.82	-46.33	-53.70	-65.14	-108	-118	-128	-136	-150	-161
Additional Paid-In Capital	56.4%	417	266	262	258	254	250	246	239	236	233	231	227	225	223	222	220	218	216	214	213	212
Shares Outstanding	10.2%	118	107	107	107	106	105	103	103	103	103	103	104	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,341	-	-	-	666	-	-	-	551,582	-	-	-	445	-	-	-	368	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-42.6%	31,925	55,648	45,128	30,754	12,070	40,077	41,301	26,191	8,478	19,176	21,707	15,675	3,814	13,105	11,451	13,265	7,213	12,292	16,263	14,074	-8,016
Share Based Compensation	94.1%	8,248	4,250	3,810	3,298	2,892	1,926	2,055	2,023	1,903	1,472	1,512	1,518	1,571	1,470	1,478	1,794	1,519	1,150	817	925	933
Cashflow From Investing	99.5%	-199	-38,318	-92,817	-	-162,367	-	-132	-	-	-41.00	-68.00	-4,001	-6,911	-	-10,011	-	5,000	31,659	5,047	-9,930	10,449
Cashflow From Financing	21310.4%	141,049	-665	-10,127	-214	149	2,253	3,984	-2,992	-1,551	-2,526	-2,098	-3,707	188	26.00	614	36.00	26.00	578	256	193	89.00
Buy Backs	-	-	-	-	-	-	-7.00	4.00	4,356	2,551	3,052	5,100	3,668	293	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CPRX Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Revenues:

Total revenues

$ 98,509

$ 85,366

Operating costs and expenses:

Cost of sales

^[1]

12,520

9,946

Research and development

2,581

3,562

Selling, general and administrative

^[1]

46,938

29,718

Amortization of intangible assets

9,344

6,531

Total operating costs and expenses

71,383

49,757

Operating income

27,126

35,609

Other income, net

1,963

1,704

Net income before income taxes

29,089

37,313

Income tax provision

5,814

7,745

Net income

$ 23,275

$ 29,568

Net income per share:

Basic

$ 0.2

$ 0.28

Diluted

$ 0.19

$ 0.26

Weighted average shares outstanding:

Basic

116,806,117

105,561,229

Diluted

123,403,626

113,986,129

Net income

$ 23,275

$ 29,568

Other comprehensive income (Note 4):

Unrealized gain (loss) on available-for-sale securities, net of tax of $4 and $5, respectively

(14)

(13)

Comprehensive income

23,261

29,555

Product revenue, net [Member]

Revenues:

Total revenues

98,441

85,304

License and other revenue [Member]

Revenues:

Total revenues

$ 68

$ 62

[1]	exclusive of amortization of intangible assets

CPRX Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 310,411	$ 137,636
Accounts receivable, net	60,493	53,514
Inventory	19,953	15,644
Prepaid expenses and other current assets	13,745	12,535
Total current assets	404,602	219,329
Operating lease right-of-use asset	2,440	2,508
Property and equipment, net	1,308	1,195
License and acquired intangibles, net	184,705	194,049
Deferred tax assets, net	38,276	36,544
Investment in equity securities	15,345	16,489
Total assets	646,676	470,114
Current Liabilities:
Accounts payable	10,261	14,795
Accrued expenses and other liabilities	69,305	61,268
Total current liabilities	79,566	76,063
Operating lease liability, net of current portion	3,091	3,188
Other non-current liabilities	2,607	2,982
Total liabilities	85,264	82,233
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value, 200,000,000 shares authorized; 118,029,526 shares and 107,121,549 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	118	107
Additional paid-in capital	416,747	266,488
Retained earnings	144,547	121,272
Accumulated other comprehensive income (Note 4)	0	14
Total stockholders' equity	561,412	387,881
Total liabilities and stockholders' equity	$ 646,676	$ 470,114

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CEO	Mr. Patrick J. McEnany
WEBSITE	catalystpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	82

Catalyst Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Catalyst Pharmaceuticals Inc? What does CPRX stand for in stocks?

CPRX is the stock ticker symbol of Catalyst Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Catalyst Pharmaceuticals Inc (CPRX)?

As of Fri May 17 2024, market cap of Catalyst Pharmaceuticals Inc is 1.95 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CPRX stock?

You can check CPRX's fair value in chart for subscribers.

What is the fair value of CPRX stock?

You can check CPRX's fair value in chart for subscribers. The fair value of Catalyst Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Catalyst Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CPRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Catalyst Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CPRX is over valued or under valued. Whether Catalyst Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Catalyst Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CPRX.

What is Catalyst Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CPRX's PE ratio (Price to Earnings) is 29.91 and Price to Sales (PS) ratio is 4.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CPRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Catalyst Pharmaceuticals Inc's stock?

In the past 10 years, Catalyst Pharmaceuticals Inc has provided 0.243 (multiply by 100 for percentage) rate of return.